Mechanisms of Cell Death and Approaches to Neuroprotection/Disease Modification in Parkinson’s Disease
- 1st Edition, Volume 2 - November 10, 2021
- Imprint: Academic Press
- Editors: Benjamin Dehay, Erwan Bezard
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 8 9 9 4 3 - 7
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 9 9 4 4 - 4
Mechanisms of Cell Death and Approaches to Neuroprotection/Disease Modification in Parkinson’s Disease explores the results of numerous studies surrounding in vitro and animal mod… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteMechanisms of Cell Death and Approaches to Neuroprotection/Disease Modification in Parkinson’s Disease explores the results of numerous studies surrounding in vitro and animal model evidence that looks at the impact of α-synucleinopathy on neuronal dysfunction and behavioral impairments, (ii) how research in animal models supports the development of therapeutic strategies, and (iii) how findings in animal models might relate to the disease process in humans. In this book, the author's shed light upon the complex scenario of the mechanisms of cell death and approaches to neuroprotection/disease modification in PD, both in vitro to in vivo.
Along with degeneration, the pathological hallmark of PD is the presence of intraneuronal proteinaceous cytoplasmic inclusions, named Lewy Bodies (LB) that invade the whole nervous system as the disease progresses. Several fundamental discoveries have shed light upon the implication of the α-syn protein in the pathogenesis of familial and sporadic forms of PD. Other proteins also accumulate in LB, but α-syn is a major protein component of the pathological landmarks.
- Updates on the latest research surrounding Mechanisms of Cell Death in Parkinson’s Disease
- Includes In vitro and In vivo models of synucleinopathy
- Presents therapeutic strategies in Parkinson’s Disease
Neurobiologists involved in in vitro and animal modeling, therapeutic approaches development, who are particularly interested in PD, and more broadly in synucleinopathies
- Cover
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter One: Alpha-synuclein spreading mechanisms in Parkinson's disease: The role of membrane receptors
- Abstract
- 1: Introduction
- 2: Physiological and pathological role of αSyn in PD
- 3: Prion-like properties of αSyn
- 4: Braak staging: The beginning of the prion-like hypothesis for αSyn
- 5: αSyn strains and spreading in neurodegeneration
- 6: Mechanisms of αSyn release and uptake
- 7: Therapeutic approaches to target extracellular αSyn
- 8: Conclusions
- Acknowledgements
- References
- Further reading
- Chapter Two: Modeling synucleinopathies in rodents
- Abstract
- 1: Introduction
- 2: Transgenic models for synucleinopathies
- 3: Viral-vector-based αSyn models for synucleinopathies
- 4: Seeding models
- Acknowledgments
- References
- Chapter Three: Spreading of alpha-synuclein pathology from the gut to the brain in Parkinson's disease
- Abstract
- 1: Introduction
- 2: Evidence for the spread of alpha-synuclein in Parkinson's disease
- 3: Factors modulating the spreading of alpha-synuclein pathology
- 4: Concluding remarks
- References
- Chapter Four: PINK1: Multiple mechanisms of neuroprotection
- Abstract
- 1: Introduction
- 2: PINK1 structure and expression
- 3: PINK1 and mitochondrial quality control
- 4: New directions for PINK1 in PD research
- 5: Conclusions
- Acknowledgments
- References
- Chapter Five: Mechanisms of VPS35-mediated neurodegeneration in Parkinson's disease
- Abstract
- 1: Introduction
- 2: Conclusion
- Acknowledgments
- References
- Chapter Six: Proteostasis impairment and ER stress as a possible target to treat Parkinson's disease
- Abstract
- 1: Introduction
- 2: UPR signaling
- 3: ER stress in Parkinson's disease
- 4: Modulation of the UPR to enhance neuronal survival in PD
- Concluding remarks
- References
- Chapter Seven: Immune response during idiopathic Parkinson's disease: From humans to animal models
- Abstract
- 1: Introduction
- 2: Idiopathic PD and a-syn
- 3: The immune system—The ability to tolerate self while defending the body
- 4: The immune components of the CNS
- 5: Inflammation in PD
- 6: A-syn and microgliosis in PD
- 7: Leukocyte infiltration to the brain during neuroinflammation in PD
- 8: Soluble biomarkers of inflammation in the CNS and periphery
- 9: Cellular immune changes found in PD blood
- 10: Overview and conclusion
- References
- Edition: 1
- Volume: 2
- Published: November 10, 2021
- No. of pages (Hardback): 314
- No. of pages (eBook): 314
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780323899437
- eBook ISBN: 9780323899444
BD
Benjamin Dehay
INSERM Research Associate, obtained his PhD from the University of Paris VI in 2007, under the supervision of Dr. Bertolotti, in the context of Huntington’s disease. He was then trained as a postdoctoral researcher at the laboratory of Dr. Vila in Barcelona, where his work mainly focused on the molecular mechanisms of neuronal cell death and the mechanism and significance of Lewy body formation in Parkinson’s disease. Since 2010, he has been working in the Institute of Neurodegenerative Diseases Research Group of Dr. Bezard, first as a senior postdoctoral fellow, where he subsequently obtained an Independent Investigator position as an INSERM Research Associate in 2013. Dr. Dehay’s scientific career has been focused to understand how the disease proteins cause alterations of the autophagy-lysosomal pathway, contributing to the pathogenesis for then proposing adapted therapeutic approaches to clear the toxic proteins and halt the disease process. He has a broad expertise in the field and in molecular and cell biology approaches and pathophysiological investigations in animal models including non-human primates, rodent models and on human tissues. Finally, some of the scientific highlights include the study of the progressive spreading of synucleinopathy through disease modeling across species.
Affiliations and expertise
University of Bordeaux, CNRS, IMN, Bordeaux, FranceEB
Erwan Bezard
INSERM Research Director, has authored or co-authored over 300 professional publications in the field of neurobiology, most of which are on Parkinson's disease and related disorders. Listed among of the most cited neuroscientists, he is known for his work on the compensatory mechanisms that mask the progression Parkinson's disease, the pathophysiology of levodopa-induced dyskinesia, the intimate mechanisms of cell death in Parkinson’s disease, the modelling of disease progression and the development of new strategies to alleviate symptoms and/or to slow disease progression. Bezard has funded in 2010, and headed until 2020, a CNRS research unit located in Bordeaux, the Institute of Neurodegenerative Diseases, which features preclinical and clinical researchers working towards development of therapeutic solutions. He is also a Visiting Professor at the China Academy of Medical Sciences (Beijing, China) where he has set-up and manages a non-human primate facility dedicated to Movement Disorders.
Affiliations and expertise
University of Bordeaux, CNRS, IMN, Bordeaux, FranceRead Mechanisms of Cell Death and Approaches to Neuroprotection/Disease Modification in Parkinson’s Disease on ScienceDirect